To investigate the underlying mechanism through which CCT3 facilitates resistance to Sorafenib in HCC, a comprehensive analysis of cellular proteomics was conducted to identify alterations in protein expression in 97 L and LM3 cells following treatment with Sorafenib and inhibition of CCT3 expression (Fig. 3A, Supplementary Table 2). This evidence concerns the gene CCT3 and hepatocellular carcinoma.